JOURNAL ARTICLE
RESEARCH SUPPORT, NON-U.S. GOV'T
Add like
Add dislike
Add to saved papers

Genotyping acaricide resistance profiles of Rhipicephalus microplus tick populations from communal land areas of Zimbabwe.

Acaricide resistance is one of the greatest threats towards the successful control of vector ticks worldwide. Communal farmers of Zimbabwe use amitraz as the most common acaricide with occasional usage of pyrethroids and organophosphates. As a strategy towards developing an effective acaricide resistance management system in Zimbabwe, screening was done by genotyping Rhipicephalus microplus tick populations using molecular markers associated with resistance to these chemicals. The frequency of the mutant allele for the octopamine/tyramine receptor marker associated with amitraz resistance was high (0.55) and a large proportion 78.5% (288/367) of heterozygote genotypes were observed indicating balancing selection. Of the communal dipping tanks where R. microplus occurred 37.8% (39/103) showed complete resistance genotypes for amitraz. The carboxylesterase marker that has been associated with resistance to organophosphate and pyrethroids indicated no selection pressure in these chemical groups with a low frequency (0.052) of the mutant allele and 89.6% (329/367) sampled ticks showing homozygous susceptibility genotypes. Heterozygous genotypes were present at 27.2% (28/103) of the dipping tanks. The L641 mutation in the voltage-gated sodium channel gene associated with pyrethroid resistance was not detected in Zimbabwean samples. This would suggest a different mechanism of resistance to pyrethroids in these tick populations. Sequence analysis of the octopamine/tyramine receptor gene revealed the presence of other mutations in this region, it will be important to investigate their association with amitraz resistance. These results present the first molecular genotyping of resistance profiles of R. microplus tick populations from Zimbabwe.

Full text links

We have located links that may give you full text access.
Can't access the paper?
Try logging in through your university/institutional subscription. For a smoother one-click institutional access experience, please use our mobile app.

Related Resources

For the best experience, use the Read mobile app

Mobile app image

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app

All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.

By using this service, you agree to our terms of use and privacy policy.

Your Privacy Choices Toggle icon

You can now claim free CME credits for this literature searchClaim now

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app